Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WXFL10203614 in Moderate to Severe Active Rheumatoid Arthritis
CTR20202463Phase 2Completed
- Sponsor
- Wuxi Fuxin Pharmaceutical Research and Development
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXFL10203614 in rheumatoid arthritis (RA), sponsored by Wuxi Fuxin Pharmaceutical Research and Development. Started Dec 2020; status: completed.
02
Drugs
WXFL10203614
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20202463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202463.